✦ LIBER ✦

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

✍ Scribed by A. Chan; S. R. McGregor

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost Utility of Sequential Adjuvant Tras

✍ Shelby D. Reed; Kevin A. Schulman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PCN81 A Cost-Effectiveness Analysis of A

✍ Buendia rodriguez, J.A.; Vallejos, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

An Economic Evaluation of Adjuvant Trast

✍ Wen Chen; Zefei Jiang; Zhimin Shao; Qiang Sun; Kunwei Shen 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Management and Outcome of HER2-Positive

✍ Carlo Palmieri; Deep Shah; Jonathan Krell; Ondrej Gojis; Katy Hogben; Pippa Ridd 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 432 KB

Non-initiation and early discontinuation

✍ Neugut, Alfred I.; Hillyer, Grace Clarke; Kushi, Lawrence H.; Lamerato, Lois; Le 📂 Article 📅 2014 🏛 Springer Japan 🌐 English ⚖ 224 KB

2-year follow-up of trastuzumab after ad

✍ Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyerei 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 183 KB